Unicycive Advances Drug Candidate Through FDA Review With Manufacturing Compliance Victory

Unicycive Therapeutics has cleared a major regulatory hurdle in its development of oxylanthanum carbonate, a potential treatment for hyperphosphatemia—a serious complication affecting dialysis patients with chronic kidney disease. The biotech firm resubmitted its New Drug Application to the FDA on Monday, marking a significant step forward after the agency's Complete Response Letter in June 2025.

The resubmission comes after the company's manufacturing partner successfully resolved compliance deficiencies that had previously delayed approval. This achievement demonstrates that the third-party vendor has regained FDA inspection readiness and addressed the single compliance issue flagged during the initial review. For dialysis patients struggling with phosphorus management, oxylanthanum carbonate represents a potentially valuable therapeutic option.

"We've made real progress with our manufacturing partner on FDA compliance matters," stated Chief Executive Officer Shalabh Gupta, M.D. The executive emphasized that the company's financial position remains solid, with cash reserves sufficient to sustain operations through 2027, providing adequate runway to navigate the regulatory approval process and prepare commercial launch activities if the NDA receives approval.

The market has responded positively to the regulatory momentum. Unicycive Therapeutics shares closed Friday's session at $6.07 per share, reflecting a gain of 3.58% and signaling investor confidence in the company's clinical and regulatory progress.

The oxylanthanum carbonate candidate addresses a critical medical need in chronic kidney disease management. Hyperphosphatemia control remains challenging for dialysis patients, and new therapeutic options with improved efficacy or tolerability profiles could significantly impact treatment outcomes. With manufacturing compliance now in place and FDA review ongoing, Unicycive is positioned to potentially bring this carbonate-based therapy to market within its current financial timeline.